- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Molecular Targeting & PARPi Strategies in mCRPC | EIOC Journal Club | Feb 2026
Integral Approaches in Molecular Targeting & PARPi Combination Strategies in mCRPC | EIOC Journal Club
Join leading oncology experts as they discuss cutting-edge molecular targeting approaches and PARP inhibitor combination strategies for metastatic castration-resistant prostate cancer (mCRPC).
📅 Originally Aired: February 2, 2026
⏰ Duration: 1 hour
🎯 Target Audience: Healthcare professionals in oncology and urology
Featured Expert Panel:
• Dr. Ammar Madani (Qatar)
• Dr. Jamila Bir Omar (Oman)
• Dr. Yahia Ismail (Bahrain)
• Dr. Deborah Mukherjee (UAE)
• Dr. Farooq Latif (UAE)
• Dr. Mohamed Hourani (UAE)
Moderated by: Dr. Shaheenah Dawood (UAE)
Key Topics Covered:
✓ Molecular targeting strategies in advanced prostate cancer
✓ PARP inhibitor combinations and sequencing
✓ Patient selection and biomarker-driven approaches
✓ Latest clinical evidence and trial data
✓ Practical management guidelines for mCRPC
Supported by: AstraZeneca
Congress Secretariat: IADEX Conventions
This complimentary educational session provides practicing healthcare professionals with expert insights on optimizing treatment strategies for metastatic castration-resistant prostate cancer.
🔗 Catch up on demand: apmeaoncology.com
#ProstateCancer #mCRPC #PARPInhibitors #MolecularTargeting #Oncology #Urology #MedicalEducation #UAE #CME #EIOC #JournalClub #APMEA
Видео Molecular Targeting & PARPi Strategies in mCRPC | EIOC Journal Club | Feb 2026 канала Dr. Shaheenah Dawood
Join leading oncology experts as they discuss cutting-edge molecular targeting approaches and PARP inhibitor combination strategies for metastatic castration-resistant prostate cancer (mCRPC).
📅 Originally Aired: February 2, 2026
⏰ Duration: 1 hour
🎯 Target Audience: Healthcare professionals in oncology and urology
Featured Expert Panel:
• Dr. Ammar Madani (Qatar)
• Dr. Jamila Bir Omar (Oman)
• Dr. Yahia Ismail (Bahrain)
• Dr. Deborah Mukherjee (UAE)
• Dr. Farooq Latif (UAE)
• Dr. Mohamed Hourani (UAE)
Moderated by: Dr. Shaheenah Dawood (UAE)
Key Topics Covered:
✓ Molecular targeting strategies in advanced prostate cancer
✓ PARP inhibitor combinations and sequencing
✓ Patient selection and biomarker-driven approaches
✓ Latest clinical evidence and trial data
✓ Practical management guidelines for mCRPC
Supported by: AstraZeneca
Congress Secretariat: IADEX Conventions
This complimentary educational session provides practicing healthcare professionals with expert insights on optimizing treatment strategies for metastatic castration-resistant prostate cancer.
🔗 Catch up on demand: apmeaoncology.com
#ProstateCancer #mCRPC #PARPInhibitors #MolecularTargeting #Oncology #Urology #MedicalEducation #UAE #CME #EIOC #JournalClub #APMEA
Видео Molecular Targeting & PARPi Strategies in mCRPC | EIOC Journal Club | Feb 2026 канала Dr. Shaheenah Dawood
Комментарии отсутствуют
Информация о видео
23 февраля 2026 г. 10:32:11
01:02:38
Другие видео канала
Dr. Olumuyiwa Adeboye | Delayed recognition of palliative care | EIOC 2023
EIOC JC - Translating Evidence to Care: BEV + PARPi for Advanced Ovarian Cancer Management
Emerging Evidence in Endocrine Resistance and SERD-Based Strategies: Clinical Perspectives
Dr.Javier Cortes | Critical Insights for Metastatic Breast Cancer Management | EIOC 2023
Dr Shaheenah Dawood x Prof Stephen Johnston: Post-ESMO 2025 Reflections on Breast Cancer Care
Meet the Expert : Dr. Shaheenah Dawood, MBBCh, FRCP (Glasgow), FRCP (Edin.), FACP, MPH
EIOC JC l Treatment Approaches for Early NSCLC Without Actionable Mutations
Recent Advances and Future Treatment Landscape of Hr+ BC
Prof. Sanjay Popat | Critical Insights for Lung Cancer Management | EIOC 2023
Novartis Symposium: Shaping Tomorrow, Redefining Risk in HR+Her2- eBC
Dr. Michael Gnant | Potential benefits of innovative drugs | EIOC 2023
Roche Symposium: Navigating Endocrine Resistance: Tailoring sequential treatments in HR+ mBC
EIOC - In Conversation Series - ESMO REFLECTIONS AND DATA SHIFTS: BREAST ONCOLOGY - Nov 6, 2025
HR +ve/HER2 –ve Breast Cancer : Reflections from 2025
EIOC - ICS - POST ESMO BREAST CANCER UPDATES , NOV 10, 2025
EIOC Fireside Chat Prof Francois Clement Bidard AZ
MSD Symposium: Immunotherapy and Chemotherapy Treatments in Early-Stage TNBC
MDT Talks on Resectable GC & GEJ | EIOC JC | March 2026
AstraZeneca Symposium: Evidence to Action in First-Line HER2+: Early and Metastatic Decisions
EGFRm NSCLC: New Era in Upfront Treatment | EIOC Journal Club | Feb 2026
